Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorKondoh, Hiroshi
dc.contributor.authorCastellví Vives, Josep
dc.contributor.authorLleonart Pajarin, Matilde
dc.date.accessioned2021-12-07T13:39:37Z
dc.date.available2021-12-07T13:39:37Z
dc.date.issued2021-04
dc.identifier.citationKondoh H, Castellvi J, LLeonart ME. Editorial: How Do Metabolism, Angiogenesis, and Hypoxia Modulate Resistance? Front Oncol. 2021 Apr;11:671222.
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/11351/6664
dc.descriptionCancer resistance; Cancer stem cell; Therapy
dc.description.abstractMetabolic alterations were among the first discovered hallmarks of cancer. They were first described 90 years ago when Otto Warburg realized that cancer cells in culture had a relatively increased metabolic rate (the Warburg hypothesis). It has been proposed that the drastic changes seen in cancer metabolism are in part attributed to mutations in the mtDNA, metabolic reprogramming, or mitochondrial dysfunction. However, novel players in cancer metabolism are emerging.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Oncology;11
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCàncer - Tractament
dc.subjectAutofàgia
dc.subject.meshNeoplasms
dc.subject.mesh/therapy
dc.subject.meshAutophagy
dc.titleEditorial: How Do Metabolism, Angiogenesis, and Hypoxia Modulate Resistance?
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fonc.2021.671222
dc.subject.decsneoplasias
dc.subject.decs/terapia
dc.subject.decsautofagia
dc.relation.publishversionhttps://doi.org/10.3389/fonc.2021.671222
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Kondoh H] Geriatric Unit, Kyoto University Hospital, Kyoto, Japan. [Castellvi J] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [LLeonart ME] Grup de Recerca Biomèdica en Cèl·lules Mare del Càncer, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology, CIBERONC, Madrid, Spain
dc.identifier.pmid33912471
dc.identifier.wos000643704800001
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F01262
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record